Literature DB >> 1069027

Cell-mediated destruction of human leukemic cells by MHC identical lymphocytes: requirement for a proliferative trigger in vitro.

P M Sondel, C O'Brien, L Porter, S F Schlossman, L Chess.   

Abstract

These experiments have investigated cellular mechanisms involved in the generation of cellular immune responses to human acute leukemic blasts. Because normal human lymphocytes are not able to recognize immunologically, in vitro, lymphocytes from MHC identical siblings, the present studies have examined the in vitro proliferative and cytotoxic responses of normal lymphocytes to MHC identical AML and ALL blasts. In those cases where acute leukemic cells were unable to induce a proliferative response by MHC identical lymphocytes, the generation of effective anti-leukemic cytotoxicity required the addition of unrelated stimulating cells to the sensitization culture. In contrast, leukemic blasts that induced a proliferative response by MHC identical lymphocytes were also able to stimulate anti-leukemic cytotoxicity. This could be augmented by the addition of unrelated stimulating cells to the sensitization culture. The specificity of anti-leukemic cell cytotoxicity was demonstrated in all instances by simultaneous testing of putative killer cells on 51Cr leukemic blasts as well as 51Cr-labeled MHC identical phytohemagglutinin blasts or normal lymphocytes. Simultaneous sensitization to MHC identical leukemic blasts and unrelated stimulating lymphocytes did not invariably generate anti-leukemic cytotoxicity even when allogeneic cytotoxicity was observed; the absence of demonstrable suppressor activity in these nonreactive combinations suggested that some individuals may be specifically immunoincompetent, and thereby unable to generate effective anti-leukemic CML.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1069027

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  15 in total

Review 1.  Human tumor-associated antigens identified by monoclonal antibodies.

Authors:  K E Hellström; I Hellström; J P Brown
Journal:  Springer Semin Immunopathol       Date:  1982

2.  In vitro generation of effector cells cytotoxic to autologous targets from chronic myeloid leukemia patients in remission.

Authors:  R Somasundaram; S G Rao; S H Advani; S G Gangal
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

3.  WI-1, a novel 120-kilodalton surface protein on Blastomyces dermatitidis yeast cells, is a target antigen of cell-mediated immunity in human blastomycosis.

Authors:  B S Klein; P M Sondel; J M Jones
Journal:  Infect Immun       Date:  1992-10       Impact factor: 3.441

4.  The role of allogeneic cells in the stimulation of cell-mediated cytotoxicity to leukaemia cells. A family study.

Authors:  G M Taylor; B A Bradley
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

5.  Autologous mixed lymphocyte reaction in patients with Hodgkin's disease. Evidence for a T cell defect.

Authors:  E G Engleman; C J Benike; R T Hoppe; H S Kaplan; F R Berberich
Journal:  J Clin Invest       Date:  1980-07       Impact factor: 14.808

6.  Cell-mediated immune responses between HLA-identical siblings: recognition of antigenic changes associated with acute myelogenous leukaemia.

Authors:  K S Zier; C Huber; E Albert; H Braunsteiner
Journal:  Clin Exp Immunol       Date:  1980-04       Impact factor: 4.330

7.  Susceptibility of human leukaemias to cell-mediated cytotoxicity by interferon-treated allogeneic lymphocytes.

Authors:  M Moore; G M Taylor; W J White
Journal:  Cancer Immunol Immunother       Date:  1982       Impact factor: 6.968

8.  HLA identical leukemia cells and T cell growth factor activate cytotoxic T cell recognition of minor locus histocompatibility antigens in vitro.

Authors:  P M Sondel; J A Hank; T Wendel; B Flynn; M J Bozdech
Journal:  J Clin Invest       Date:  1983-06       Impact factor: 14.808

9.  Antitumor activity in vitro in chronic myelogenous leukaemia revealed after treating peripheral cells with cytosine arabinoside.

Authors:  G Pawelec; H Schmidt; A Rehbein; F Busch
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

10.  Mechanisms by which human gliomas may escape cellular immune attack.

Authors:  M K Gately; M Glaser; R M McCarron; S J Dick; M D Dick; R W Mettetal; P L Kornblith
Journal:  Acta Neurochir (Wien)       Date:  1982       Impact factor: 2.216

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.